This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anderson, H. V. Search for Related Content PubMed PubMed Citation Articles by Anderson, H. V.

(Circulation. 1996;94:1809-1811.)
© 1996 American Heart Association, Inc.

Articles

Estrogen Therapy, Atherosclerosis, and Clinical Cardiovascular Events

H. Vernon Anderson, MD

the University of Texas Health Science Center, Houston.

Correspondence to H. Vernon Anderson, MD, Department of Internal Medicine, UT Health Science Center–Houston, 6431 Fannin, PO Box 20708, Houston, TX 77225.

Key Words: Editorials • hormones • atherosclerosis

	Introduction

 
In this issue of Circulation, Nabulsi and coworkers¹ from the Atherosclerosis Risk in Communities (ARIC) Study Group report their findings on the association of age, menopause status, and hormone replacement therapy with a single measure of atherosclerosis: the average carotid artery intima-media thickness determined by B-mode ultrasound. What they discovered in the ARIC cohorts was this: there was little or no relation between menopausal staus and carotid thickness in women aged 45 to 54 who had never used hormonal therapy and who had no evidence of coronary heart disease at entry. Furthermore, for slightly older (aged 55 to 64 years) postmenopausal women, there was no relation between the number of years since menopause and carotid thickness nor between hormone use and carotid thickness. All of these findings were unexpected. Data that have been accumulated over the past few years demonstrate strong clinical benefits from estrogen use for postmenopausal women. The ARIC investigators quite logically hypothesized that there would be significant relations between carotid thickness, menopause, and hormone therapy (or lack of it) in this community-wide study, but in fact their data did not provide support for this. The investigators speculate that the association of estrogen replacement therapy with a reduction in clinical cardiovascular events after menopause may not necessarily be due to a reduction in the amount of anatomic atherosclerotic disease or inhibition of its formation, at least during the early years after menopause, but might instead be more attributable to other beneficial physiological changes brought about by estrogen . . . [Full Text of this Article]

This article has been cited by other articles:

				K. H. Humphries and S. Gill Risks and benefits of hormone replacement therapy: The evidence speaks Can. Med. Assoc. J., April 15, 2003; 168(8): 1001 - 1010. [Abstract] [Full Text] [PDF]

				C. N. Mhurchu, C. Anderson, K. Jamrozik, G. Hankey, D. Dunbabin, W.T. Longstreth Jr, and L. M. Nelson Hormonal Factors and Risk of Aneurysmal Subarachnoid Hemorrhage : An International Population-Based, Case-Control Study Editorial Comment : The Gender Gap in Aneurysmal Subarachnoid Hemorrhage Stroke, March 1, 2001; 32(3): 606 - 612. [Abstract] [Full Text] [PDF]